D-0137-2017 Class III Terminated

Recalled by Amerisource Health Services — Columbus, OH

FDA drug recall D-0137-2017 was initiated by Amerisource Health Services on Oct 27, 2016 and is designated Class III. Reason for recall: Failed Dissolution Specifications: The firm was notified that there was a dissolution out of specification result on the 6 month stability samples. The recall status is terminated (terminated Jun 29, 2017). Affected quantity: a) 15,409 bottles b) 5,128 bottles.

Recall details

Product Type
Drugs
Report Date
Nov 23, 2016
Initiation Date
Oct 27, 2016
Termination Date
Jun 29, 2017
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
a) 15,409 bottles b) 5,128 bottles

Product description

Bupropion Hydrochloride Extended-Release Tablets, USP (XL), 300 mg, a) 90-count bottle (NDC 68001-264-05), b) 500-count bottle (NDC 68001-264-03) , Rx only, Manufactured by: Cadila Healthcare Limited, Ahmedabad, India For BluePoint Laboratories

Reason for recall

Failed Dissolution Specifications: The firm was notified that there was a dissolution out of specification result on the 6 month stability samples.

Distribution pattern

Nationwide and Puerto Rico

Code information

Lot #: a) M601509, Exp 3/31/2018; M606506, Exp 4/30/2018; b) M601510, Exp 3/31/2018; M604444, Exp 4/30/2018; M606515, Exp 4/30/2018.

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0137-2017
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0137-2017. Report a data issue: hello@regdatalab.com.